Allele Bio files 2 patent infringement suits on mNeonGreen used in COVID vaccines

• San Diego-based Allele Biotechnology and Pharmaceuticals has filed two patent infringement lawsuits – one in New York against Regeneron Pharmaceuticals (NASDAQ:REGN) and the other in California against Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX).
• Both complaints address the infringement of Allele’s patented mNeonGreen technology, an important reagent used in the development of therapeutics for COVID-19.
• Allele’s mNeonGreen protein is considered the brightest monomeric fluorescent protein, and the technology behind that protein was patented in 2019.
• Scientific journals have touted the use of mNeonGreen for use in assays testing neutralizing antibody and vaccine candidates. Regeneron, Pfizer, and BioNTech used mNeonGreen commercially without authorization from Allele.
• “The purpose of these lawsuits is to maintain Allele's patent rights and to ensure that an agreement can be put in place to protect the rights of current and future licensees,” says Dan Catron, Executive Director, Licensing and Business Development for Allele.
• https://seekingalpha.com/news/3619990-allele-bio-files-two-lawsuits-for-patent-infringement-of-mneongreen-used-in-covidminus-19